Management remarks
Call period: 2026 Q2 · 2026-08-04
Guidance: Peter Griffith: We are pleased with our strong execution in the first half of the year, and we are raising our 2026 guidance ranges for both revenue and non-GAAP earnings per share.Demand and orders: Murdo Gordon: TEZSPIRE sales grew 42% year-over-year, reaching $486 million, driven by strong demand in severe uncontrolled asthma.Margins: Peter Griffith: We continue to expect the full year non-GAAP operating margin as a percentage of product sales to be roughly 45% to 46%.Analyst Q&A
Analyst Taylor Hanley asked: And specifically, if we do see a 13% to 15% type benefit from that study, how would you think about the potential read-throughs to Olpasiran? Management James Bradner answered: What can we expect from the pelacarsen data? We're following it with interest. We can expect perhaps some directional insight, but not decisional perspective owing to the superior properties of our molecule that delivers 95% Lp(a) reduction compared to, say, 70% with that molecule and also some differences in the study design, which we just described.管理层陈述
电话会期间：2026 Q2 · 2026-08-04
指引：我们对今年上半年的强劲执行力感到满意，并上调了2026年营收和非GAAP每股收益的指引区间。需求与订单：TEZSPIRE销售额同比增长42%，达到4.86亿美元，这得益于重度未控制哮喘领域的强劲需求。利润率：我们预计全年非GAAP产品销售营业利润率约为45%至46%。分析师问答
分析师泰勒·汉利提问称，如果某试验显示13%至15%的类型收益，将如何评估其对Olpasiran的潜在借鉴意义，管理层詹姆斯·布拉德纳回应称，他们正关注pelacarsen的数据，仅能获得方向性见解而非决定性参考，因其旗下药物可降低95%的脂蛋白(a)，而该药物仅能降低70%，且试验设计也存在差异。This earnings-call research was prepared from company results, regulatory filings, financial statements, and earnings-call transcripts or official replays. It is for informational purposes only and does not constitute investment advice.这篇财报电话会研究基于公司公告、监管文件、财务报表，以及真实电话会文字稿或官方回放整理。内容仅供参考，不构成投资建议。
